Dublin, Oct. 06, 2021 (GLOBE NEWSWIRE) -- The "mRNA: Therapeutics and Global Markets 2021-2026" report has been added to ResearchAndMarkets.com's offering.
The global market for mRNA therapeutics should grow from $46.7 billion in 2021 to $101.3 billion by 2026, at a compound annual growth rate (CAGR) of 16.8% for the period of 2021-2026.
The U.S. market for mRNA therapeutics should grow from $21.5 billion in 2021 to $46.5 billion by 2026, at a CAGR of 16.7% for the period of 2021-2026.
The Asia-Pacific market for mRNA therapeutics should grow from $6.1 billion in 2021 to $13.8 billion by 2026, at a CAGR of 17.9% for the period of 2021-2026.
This report is an analytical business tool with the primary purpose of providing a thorough evaluation of the global market for mRNA therapeutics for the prevention of infectious diseases (through prophylactic vaccines) and treatment of chronic (e.g., cancer, heart diseases) and several other rare diseases.
The report considers only "Western" or modern drugs and excludes any other type of drugs such as alternative therapies. This report covers technologies used for the development and delivery of mRNA therapeutics.
This study aims to analyze the dynamics and forecasts of the mRNA therapeutics market worldwide and provides key market propositions over a five-year forecast period.
32 data tables and 32 additional tables
An overview of the global market for mRNA therapeutics
Analyses of global market trends with data from 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
Highlights of the major developments, pandemic threats, therapeutic developments, and technological developments of the mRNA therapeutics market
Discussion on significant advantages of mRNA over protein or DNA-based delivery systems and description of demographic and economic trends, and outlook of the mRNA therapeutics market
Evaluation of current market size and forecast and information on prophylactic vaccines, vaccine discovery and development, and R&D activities
Analysis of the various innovative therapeutics as well as new promising vaccines intended for the prevention and treatment of various chronic and infectious diseases
Assessment of regulatory structure, pricing and reimbursement scenario, and pipeline analysis of the new molecules & therapeutics
Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
Comprehensive company profiles of major players of the industry, including Amgen Inc., Eli Lilly and Co., GlaxoSmithKline Plc, Johnson & Johnson and Novartis
mRNA therapeutics have emerged as a rapidly growing field with multibillion-dollar business potential within the biotherapeutics market. The therapeutic use of mRNA is unique and powerful since it plays a very critical role in human biology and instruct cells to make proteins to circulate throughout the body.
Recent commercial success has shown its potential to transform the biopharma industry, the same way that the first-generation biotech companies (such as Amgen, Biogen and Genentech) did in the 1980s when they began developing recombinant protein therapies called biologics. The COVID-19 pandemic became the first pandemic of the current generation. It created lots of mRNA buzz in the market in terms of appreciating the bigger picture of the mRNA segment and its wider potential of developing precise and individualized therapies targeting diseases beyond viral infections.
Revenue from 2021 is an estimate based on sales of the first two quarters (Q1 & Q2) along with projections of dose orders for 2021 by leading companies. mRNA therapeutics typically include vaccines, drugs and therapies developed through mRNA technology. This market growth is fueled by the increasing incidence of infectious diseases (e.g., COVID-19, Zika, influenza, Ebola, etc.); increasing prevalence of chronic diseases (e.g., cancer, heart diseases, respiratory, CKD, etc.), rare diseases (e.g., methylmalonic acidemia, propionic acidemia, phenylketonuria, glycogen disease, etc.), and metabolic and immune disorders; commercialization of mRNA vaccines; development of personalized therapeutics for cancer; strong pipeline of therapeutics addressing the unmet need for rare diseases; and growing global acceptance for mRNA therapeutics (e.g., COVID-19, Ebola, influenza, HIV) over traditional drugs and vaccines.
The market for 2020 is relatively lower since BioNTech and Moderna received emergency approvals for their vaccines in December 2020. Additionally, 2021 revenue is also an estimate based on sales of first two quarters (Q1 and Q2) along with projections of doses ordered to be delivered by 2021, by leading companies. The U.S. is expected to maintain dominance in the mRNA therapeutics market. This growth is due to the growing geriatric population, rise of COVID-19 pandemic, increasing incidence of infectious diseases, increasing prevalence of chronic diseases, growing demand for transformative therapeutics, increasing acceptance of mRNA vaccines, preventive care, continuous technological advancements, increasing investment, incentives for new product development, unmet need for rare disease treatment, favorable regulatory environment, acceptance of personalized medicine and increasing adoption of treatment adherence technologies and software applications.
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Target Diseases and Disorders
Overview of Common Diseases and Disorders for mRNA Therapeutics
Tobacco Smoking and Associated Diseases
Infectious Diseases: COVID-19 Pandemic Set the Stage for mRNA Therapeutics
Chronic Diseases: Expanding Horizon for mRNA Therapeutics
Rare Diseases: Large Unmet Need is Fueling mRNA Therapeutics
Ageing, Gender and Onset of Diseases
Current Challenges and Future Directions
Chapter 4 RNA Therapeutics
RNA Therapeutics Overview
Evolution of RNA Therapeutics
History of RNA Therapeutics
Development of RNA Therapeutics and Types
DNA vs. RNA Therapeutics
Clinical Need for RNA Therapeutics
Increasing Disease Population and Economic Burden
Limitations of Traditional Therapeutics
Therapeutic Limitations of Biologics
Poor Management of Chronic Diseases
Limited Treatment for Rare Diseases
Antisense Oligonucleotide (ASO) as Therapeutics
Small Interfering RNA (siRNA) as Therapeutics
miRNA as Therapeutics
Aptamers as Therapeutics
mRNA as Therapeutics
Manufacturing RNA-Based Biopharmaceuticals
Chromatographic Purification Steps
Delivery of RNA Therapeutics
Polymer Conjugation/Chemical Modification
Carbon and Gold Nanomaterials
Institution and Hospital-Based RNA Therapeutics
Regulatory Influence on the Market for RNA Therapeutics
Market Situation for RNA Therapeutics
Therapeutics and Cost Burden
Current Challenges and Future Developments
Chapter 5 mRNA Vaccines
Vaccine-Based Disease Prevention
Evolution of mRNA as Vaccine
Clinical Need for mRNA Vaccines
mRNA Vaccines and Types by Application
mRNA Vaccine Product Segments
Non-amplifying mRNA Vaccines
Self-amplifying mRNA Vaccines
Immunogenicity and mRNA Vaccines
Optimizing Injection Routes
Co-encapsulation of Other Stimulatory Molecules
Formulation and Delivery of mRNA Vaccine
Approaches for Enhancing mRNA Stability
Advantages of mRNA Vaccines
Traditional Vaccine vs. mRNA Vaccines
Marketed/Commercial mRNA Vaccines
mRNA Vaccine Pipeline and New Developments
mRNA Vaccine Pipeline by Company
mRNA Vaccines: New Developments
mRNA Vaccines and Future Pandemics
Current Challenges and Future Outlook
Chapter 6 mRNA Drugs and Therapies
Overview of Drugs and Therapeutics
Therapeutic-Based Disease Treatment
Evolution of mRNA: Beyond Vaccines
Clinical Need for mRNA Therapeutics Beyond Vaccines
mRNA Vaccines vs. mRNA Therapeutics
mRNA Therapeutics and Types
mRNA as Gene and Protein Replacement Therapy
mRNA-Enhanced Cell Therapies
mRNA-Enhanced Immunotherapies (Monoclonal Antibody)
Advantages mRNA Drugs and Therapies
Delivery of mRNA Therapeutics
mRNA Therapeutics Pipeline and New Developments
mRNA Drugs for Protein Therapy Targeting Metabolic and Rare Diseases
Pipeline for mRNA-Therapeutics by Company
Pipeline for mRNA-Enhanced Cell Therapies
mRNA Therapeutics and New Developments
Widespread Concerns over the mRNA Medicinal Industry
Issues with Personalized Medicine
Unmet Need for mRNA Therapeutics
Current Challenges and Future Outlook
Chapter 7 Market Size and Growth Analysis
Market Size and Growth Analysis by Region
Market Size and Growth Analysis by Product Segment
mRNA Vaccines vs. Traditional Vaccines
mRNA Drugs and Therapies
Market Size and Growth Analysis by Therapeutic Treatment Type
Market Size and Growth Analysis by Disease Type
Market Growth Drivers and Restraints
Market Growth Drivers
Regulatory Impact on the Market for mRNA Therapeutics
SWOT Analysis of the Market for mRNA Therapeutics
Chapter 8 Competitive Landscape in the Market for mRNA Therapeutics
Disease Prevention and Treatment with mRNA Therapeutics
Chapter 9 Strategies in the Market for mRNA Therapeutics
Consolidation in the Pharmaceutical Market
Mergers and Acquisitions in the Biopharmaceutical Market
Recent Strategic Moves in mRNA Therapeutics
Key M&A and In-licensing Deals
Key Strategic Partnerships
Key Venture Financing Deals
Future Strategic Landscape
Chapter 10 Regulatory Structure for Biopharmaceuticals
Regulatory Systems for Biopharmaceuticals by Region
Regulatory Systems for Medical Devices by Region
Regulations for mRNA Therapeutics
Current Regulatory Issues for mRNA Therapeutics
Moderna Vaccine Regulation in the U.K.
Key Regulatory Updates, 2020
Chapter 11 Pricing and Reimbursement: Pharmaceuticals and Biologics
Pricing and Reimbursement Background
Pricing and Reimbursement of Pharmaceuticals and Biologics by Region
Private Health Insurance
Chronic Diseases and Cost Burden on Medicare
Rise of Infectious Diseases and Pricing & Reimbursement for Vaccines in the US.
Pricing and Reimbursement Challenges for Pharmaceuticals
Patented Medicines Price
Prices of Older Drugs
Pricing and Reimbursement for Medical Devices by Region
Other Parts of Asia-Pacific
Chapter 12 Conclusions on the Outlook for mRNA Therapeutics
Major Developments Influencing the Market
Digital Transformation and Technological Developments
Increasing R&D Spend and Shift Towards Modern Therapeutics and Technologies
Collaborations for Advanced Therapeutics
Market Consolidation for Strategic Growth and to Retain Market Leadership
Demographic and Economic Trends
Changing Structure of the Pharma and Healthcare Industry
Prevalence of Self-Care
Burden on Public Health System
Chapter 13 Company Profiles
Arcturus Therapeutics Inc.
Argos Therapeutics Inc.
Cartesian Therapeutics Inc.
Crispr Therapeutics Inc.
Eli Lilly And Co.
Elixirgen Therapeutics Inc.
Genentech (Subsidiary Of Roche)
Greenlight Biosciences Inc.
HDT Bio Corp.
Ionis Pharmaceuticals Inc.
Johnson & Johnson
Kernal Biologics Inc.
Poseida Therapeutics Inc.
Sangamo Therapeutics Inc.
Shanghai Bendao Gene Technology Co., Ltd.
Stemirna Therapeutics Ltd.
Tiba Biotechnology Llc
Chapter 14 Appendix A: List of Acronyms
Chapter 15 Appendix B: Professional Organizations
For more information about this report visit https://www.researchandmarkets.com/r/t8j6qu
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900